)
The shortage is creating havoc for mobile device manufacturers who are getting less than 30-40 per cent of the normal requirement of chips
According to the CEO, last year the company saw a V-shaped recovery after the first lockdown was lifted
French company plans to make Noida plant one of its largest production units
The leading private equity player is re-entering the start-up space after around two decades
Mediratta said e-commerce sales have gone up 10 times since they started in April 2020.
Company could help with government's desire to have a semiconductor industry.
Kant pointed out that the global supply chain is in a flux as most countries are looking at alternatives and reducing their dependence on one country
Domestic PE players include funds like Multiples, Kedara, and so on, who, along with the global PEs, form the majority of the country's PE players
A clutch of domestic companies is developing equipment and software solutions for this upcoming next-gen telecom technology
Highest investment in the sector in last 5 years; pandemic expands opportunities
If a company invests Rs 100 crore, it can account for Rs 5 crore as technology transfer and Rs 15 crore as R&D expenditure.
Thanks to Covid disruptions, office and shopping mall rentals are no longer attractive
HFCL supplies telecom equipment and fibre optics to most of the current Indian operators.
The promoters had offered a substantial portion of their equity as security for the credit facilities availed of by Essel Group
Telegram is now number one in downloads, having pushed WhatsApp to fourth position
The big two telecom players have reorganised their digital businesses in readiness to monetise them.
The country's first big-ticket SPAC listing of ReNew Power is already underway, with investors being brought in, and is expected to be listed sometime in the early third quarter of this year
The new technology, based on low earth orbit satellites (LEO), which is being used by the two companies, can offer broadband speeds of over 5GBPS
SBI says there are 15 vaccines approved for emergency use and a similar number in Phase 2 or 3 stage of development; another four are in the regulatory review stage.
The purpose is to see if the states and the Centre can use its technology to tackle the issues arising from the pandemic.